Based on 5 analysts giving stock ratings to Lifecore Biomedical Inc in the past month.
In the current month, LFCR has received 1 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. LFCR average Analyst price target in the last month is 5.640.
Based on analysts' estimates, LFCR EPS is projected to reach -0.250 in FY2026Q3, following reported EPS of -0.190 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.19, while Lifecore Biomedical IncLFCR's earnings per share (EPS) for the previous quarter was USD -0.43. EPS for the next quarter is expected at USD -0.14.